CD33 and acute myeloid leukemia: Despite the preclinical success of CD33-directed CAR-T-therapy in inducing anti-leukemic effects, in vivo targeting of AML blasts is difficult due to the overlapping expression of AML associated-antigens on progenitor and mature hematopoietic cells of the myeloid lineage.